Overview
Administration of radium-223 (Xofigo) for treatment of bone metastases from castration-resistant prostate cancer, targeting cancer that has spread to bones.
Renal / Urologic
Administration of radium-223 (Xofigo) for treatment of bone metastases from castration-resistant prostate cancer, targeting cancer that has spread to bones.
Administration of radium-223 (Xofigo) for treatment of bone metastases from castration-resistant prostate cancer, targeting cancer that has spread to bones.
The procedure is performed on an outpatient basis under image guidance. Most patients go home the same day and resume light activity within a day or two, rather than the weeks typical after open surgery.
Suitability depends on your imaging, symptoms, and medical history. Our interventional radiologists review each case with your referring physician before recommending treatment.